TMEM160 and gastric cancer: In our institutional cohort of 180 GC patients who underwent surgical treatment (clinicopathological characteristics in Supplementary Table 9), IHC analysis revealed concurrent overexpression of TMEM160 and NRF2 in tumor versus adjacent normal tissues (Fig. 8A, B and Supplementary Fig. 6C).